deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01025232

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial) (SAVE)

A Phase I/II Open Label, Multicenter Study of the Safety, Tolerability and Efficacy of Multiple Intravitreal Injections of (Super-dose Anti-VEgf SAVE Trial) 2.0mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab

Sponsor: David M. Brown, M.D.

Conditions Age Related Macular Degeneration Choroidal Neovascular Membrane Macular Degeneration Subfoveal Neovascular Age-Related Macular Degeneration Wet Age-Related Macular Degeneration
Interventions Ranibizumab
Updated 10 times since 2017 Last updated: Nov 3, 2016 Started: Dec 31, 2009 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The last remaining subject withdrew consent because the collaborator Genentech stopped supplying study drug.

Other terminated trials from David M. Brown, M.D.

More terminations from David M. Brown, M.D.

Other Age Related Macular Degeneration trials with similar outcome

Browse all Age Related Macular Degeneration trials

This PHASE1/PHASE2 trial investigates Age Related Macular Degeneration and Choroidal Neovascular Membrane and is currently terminated or withdrawn. David M. Brown, M.D. leads this study, which shows 10 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotTerminated~Aug 2017 – ~May 2018 · 9 months · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 20 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 5 earlier versions

  1. Jun 2018 — Nov 2020 [monthly]

    Terminated PHASE1_PHASE2

  2. May 2018 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

  3. Aug 2017 — May 2018 [monthly]

    Terminated PHASE1_PHASE2

  4. Feb 2017 — Aug 2017 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1_PHASE2

    First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • David M. Brown, M.D.
  • Genentech, Inc.
Data source: Greater Houston Retina Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations